Lundbeck R&D comeback hopes tied to bexicaserin study
UBS analysts said study results for Lundbeck’s epilepsy drug candidate bexicaserin could support the company’s multiyear R&D turnaround, potentially highlighting the drug’s potential.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.